The prospective comparison of angiotensin receptor and neprilysin inhibitor with ACE inhibitor to determine impact on global mortality and morbidity in HF (PARADIGM-HF trial), (NCT01035255), demonstrated that treatment with sacubitril/valsartan was superior to the ACE inhibitor, enalapril, in reducing mortality and morbidity in patients with HF with reduced ejection fraction [9]. The gene discussed is ACE; the disease is hydrops fetalis.